Vantictumab, formerly labeled as OMP18R5, represents a novel monoclonal antibody designed with specifically inhibit OPN protein 18R5. The treatment is being developed by researchers for potential treatments in multiple https://rafaelwnuc703721.wikiexpression.com/user